Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced that on December 3, 2025 its Compensation Committee granted inducement stock options to two new employees totaling 212,000 shares under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $4.49 (the closing price on the grant date), a 10-year term, and a four-year vesting schedule: 25% vest on the first anniversary of the vesting commencement date and the remaining 75% vest monthly over the next 36 months, subject to continued service.

News Market Reaction – TSHA

+7.92%

1 alert

+7.92% News Effect

On the day this news was published, TSHA gained 7.92%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options granted: 212,000 shares Exercise price: $4.49 Option term: 10 years +2 more

5 metrics

Inducement options granted 212,000 shares Aggregate options to two new employees granted Dec 3, 2025

Exercise price $4.49 Equal to TSHA closing price on grant date Dec 3, 2025

Option term 10 years Term of inducement stock options under 2023 Inducement Plan

Vesting schedule 4 years 25% at 1-year cliff, 75% monthly over 36 months thereafter

New employees 2 individuals Recipients of inducement grants under Nasdaq Listing Rule 5635(c)(4)

Market Reality Check

Price: $4.70 Vol: Volume 5,019,106 is 1.44x...

normal vol

$4.70 Last Close

Volume Volume 5,019,106 is 1.44x the 20-day average of 3,488,070 shares. normal

Technical Shares at $5.06 are trading above the 200-day MA of $2.87 and 8.14% below the 52-week high.

Peers on Argus

TSHA gained 12.69% with elevated volume, while key biotech peers like QURE, SANA...

TSHA gained 12.69% with elevated volume, while key biotech peers like QURE, SANA, EYPT, OCS, and UPB also showed positive price changes, but no sector-wide momentum signal was triggered in the scanner.

Historical Context

5 past events · Latest: Nov 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 04	Earnings and update	Positive	-4.3%	Q3 2025 results plus TSHA-102 Breakthrough Therapy designation and pivotal plan.
Oct 28	Earnings call notice	Neutral	+2.3%	Announcement of timing and access details for Q3 2025 earnings call.
Oct 16	Program rights regained	Positive	-4.9%	TSHA regained full global rights to TSHA-102 after Astellas option expiry.
Oct 09	Clinical data update	Positive	-1.2%	Supplemental Part A REVEAL data with 100% response rate and added milestones.
Oct 03	Inducement option grant	Neutral	-7.1%	Inducement stock options totaling 1,289,600 shares for seven new employees.

Pattern Detected

Recent history shows multiple positive clinical and corporate updates followed by negative next-day moves, suggesting a pattern of selling into good news, while routine items like earnings calls have had modest impact.

Recent Company History

Over the last few months, TSHA has focused on advancing TSHA-102 for Rett syndrome and strengthening its balance sheet. Key milestones included FDA Breakthrough Therapy designation, full rights regained to TSHA-102, and strong Part A REVEAL data with a 100% response rate. Q3 2025 results highlighted cash of $297.3M and a net loss of $32.7M. A prior inducement grant on Oct 1, 2025 and today’s grant both use the 2023 Inducement Plan under Nasdaq Listing Rule 5635(c)(4), reflecting ongoing hiring as programs progress.

Market Pulse Summary

The stock moved +7.9% in the session following this news. A strong positive reaction aligns with TSH...

Analysis

The stock moved +7.9% in the session following this news. A strong positive reaction aligns with TSHA trading near its 52-week highs, with shares at $5.06 and volume at 1.44x the 20-day average before this announcement. Historically, the stock often showed negative next-day moves after positive clinical and corporate news, as seen around TSHA-102 updates, suggesting a tendency for profit-taking. The current inducement grant of 212,000 options at $4.49 is small versus the reported share count in recent filings, but ongoing equity programs and an expanded at-the-market facility could influence longer-term supply dynamics.

Key Terms

Nasdaq Listing Rule 5635(c)(4), adeno-associated virus, central nervous system, exercise price

4 terms

Nasdaq Listing Rule 5635(c)(4) regulatory

"under the 2023 Inducement Plan ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

adeno-associated virus medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

central nervous system medical

"severe monogenic diseases of the central nervous system (CNS)"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

exercise price financial

"The stock options have an exercise price of $4.49 which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 3, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 212,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $4.49 which is equal to the closing price of Taysha's common stock on the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What did Taysha (TSHA) announce on December 3, 2025 about employee stock options?

Taysha granted inducement options totaling 212,000 shares to two new employees, with an exercise price of $4.49 and a 10-year term.

How does the vesting schedule work for the TSHA inducement options granted December 3, 2025?

Options vest over 4 years: 25% on the first anniversary of vesting commencement, then the remaining 75% monthly over the following 36 months, subject to continued service.

Why did Taysha (TSHA) issue the 212,000 options under the 2023 Inducement Plan?

The options were granted as an inducement material to the individuals entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and how was it determined for TSHA's December 3, 2025 grant?

The exercise price is $4.49, equal to Taysha's closing common stock price on the grant date.

Do the TSHA inducement options pose immediate dilution for shareholders?

The announcement discloses 212,000 options but does not state outstanding share count or percentage dilution, so immediate dilution magnitude is not specified.

Where can investors find details about the TSHA inducement grant under Nasdaq Rule 5635(c)(4)?

Details are provided in the company's announcement describing the number of options, exercise price, term, and vesting under the 2023 Inducement Plan.